PRODUZIONE SCIENTIFICA:
Autore di **25** pubblicazioni su riviste internazionali peer reviewed, di cui **15** pubblicazioni come primo autore. Autore di **2** capitoli di libri e **22** comunicazioni a congressi nazionali e internazionali.

Scopus: H-index = 12; Citazioni totali = 407

PUBBLICAZIONI (IF = "5-Year Impact Factor" da JCR):

1. **Scoffone VC**, Irudal S, AbuAlshaar A, Piazza A, Trespidi G, Barbieri G, Makarov V, Migliavacca R, De Rossi E, Buroni S. Bactericidal and Anti-Biofilm Activity of the FtsZ Inhibitor C109 against *Acinetobacter baumannii*. Antibiotics (Basel). 2022; 11(11):1571.
2. Pellegrini A, Lentini G, Famà A, Bonacorsi A, **Scoffone VC**, Buroni S, Trespidi G, Postiglione U, Sassera D, Manai F, Pietrocola G, Firon A, Biondo C, Teti G, Beninati C, Barbieri G. CodY Is a Global Transcriptional Regulator Required for Virulence in Group B *Streptococcus*. Front Microbiol. 2022; 13: 881549. (IF=6.320, c=0)
3. **Scoffone VC,** Trespidi G, Barbieri G, Irudal S, Israyilova A, Buroni S. Methodological tools to study species of the genus *Burkholderia*. Appl Microbiol Biotechnol. 2021; 105: 9019- 9034. (IF= 4.697, c=0)
4. **Scoffone VC**, Trespidi G, Barbieri G, Irudal S, Perrin E, Buroni S. Role of RND efflux pumps in drug resistance of Cystic Fibrosis pathogens. Antibiotics. 2021; 10:863. (IF=4.849, c=3)
5. Trespidi G*, **Scoffone VC***, Barbieri G, Marchesini F, Abualsha'ar A, Coenye T, Ungaro F, Makarov V, Migliavacca R, De Rossi E, Buroni S. Anti-staphylococcal activity of the FtsZ inhibitor C109. Pathogens. 2021; 10:886. *equal contributors (IF=4.066, c=1)
6. Barbieri G, Ferrari C, Mamberti S, Gabrieli P, Castelli M, Sassera D, Ursino E, **Scoffone VC**, Radaelli G, Clementi E, Sacchi L, Ferrari E, Gasperi G, Albertini AM. Identification of a novel *Brevibacillus laterosporus* strain with insecticidal activity against *Aedes albopictus* larvae. Front Microbiol. 2021; 12:624014. (IF=6.320 c=1)
7. Trespidi G*, **Scoffone VC***, Barbieri G, Riccardi G, De Rossi E, Buroni S. Molecular Characterization of the *Burkholderia cenocepacia dcw* operon and FtsZ interactors as new targets for novel antimicrobial design. Antibiotics (Basel). 2020; 9:841. *equal contributors (IF= 4.849, c=4)
8. Ursino E, Albertini AM, Fiorentino G, Gabrieli P, **Scoffone VC**, Pellegrini A, Gasperi G, Di Cosimo A, Barbieri G. *Bacillus subtilis* as a host for mosquitocidal toxins production. Microb Biotechnol. 2020; 13:1972-1982. (IF=6.559, c=1)
9. Chiarelli LR*, **Scoffone VC***, Trespidi G, Barbieri G, Riabova O, Monakhova N, Porta A, Manina G, Riccardi G, Makarov V, Buroni S. Chemical, Metabolic, and Cellular Characterization of a FtsZ Inhibitor Effective Against *Burkholderia cenocepacia*. Front Microbiol. 2020; 11:562. *equal contributors (IF=6.320, c=3)
10. **Scoffone VC**, Barbieri G, Buroni S, Scarselli M, Pizza M, Rappuoli R, Riccardi G. Vaccines to Overcome Antibiotic Resistance: The Challenge of *Burkholderia cenocepacia*. Trends Microbiol. 2020; 28:315-326. (IF=18.337, c=11)
11. Buroni S, Makarov V, **Scoffone VC**, Trespidi G, Riccardi G, Chiarelli LR. The cell division protein FtsZ as a cellular target to hit cystic fibrosis pathogens. Eur J Med Chem. 2020; 190:112132. (IF=6.099, c=5)
12. Costabile G, Provenzano R, Azzalin A, **Scoffone VC**, Chiarelli LR, Rondelli V, Grillo I, Zinn T, Lepioshkin A, Savina S, Miro A, Quaglia F, Makarov V, Coenye T, Brocca P, Riccardi G, Buroni S, Ungaro F. PEGylated mucus-penetrating nanocrystals for lung delivery of a new FtsZ inhibitor against *Burkholderia cenocepacia* infection. Nanomedicine. 2020; 23:102113. (IF=7.072, c=15)
13. **Scoffone VC**, Trespidi G, Chiarelli LR, Barbieri G, Buroni S. Quorum Sensing as Antivirulence Target in Cystic Fibrosis Pathogens. Int J Mol Sci. 2019; 20:1838. (IF= 4.653, c=33)
14. Hogan AM, **Scoffone VC**, Makarov V, Gislason AS, Tesfu H, Stietz MS, Brassinga AKC, Domaratzki M, Li X, Azzalin A, Biggiogera M, Riabova O, Monakhova N, Chiarelli LR, Riccardi G, Buroni S, Cardona ST. Competitive fitness of essential gene knockdowns reveals a broad-spectrum antibacterial inhibitor of the cell division protein FtsZ. Antimicrob Agents Chemother. 2018; 62:e01231-18. (IF= 4.719, c=15)

15. Buroni S*, **Scoffone VC***, Fumagalli M, Makarov V, Cagnone M, Trespidi G, De Rossi E, Forneris F, Riccardi G, Chiarelli LR. Investigating the Mechanism of Action of Diketopiperazines inhibitors of the *Burkholderia cenocepacia* Quorum Sensing synthase CepI: a site-directed mutagenesis study. Front Pharmacol. 2018; 9:836. *equal contributors (IF= 4.469, c=12)
16. Perrin E, Maggini V, Maida I, Gallo E, Lombardo K, Madarena MP, Buroni S, **Scoffone VC**, Firenzuoli F, Mengoni A, Fani R. Antimicrobial activity of six essential oils against *Burkholderia cepacia* complex: insights into mechanism(s) of action. Future Microbiology 2018; 13:59-67. (IF= 3.697, c=9).
17. Perrin E, Fondi M, Bosi E, Mengoni A, Buroni S, **Scoffone VC**, Valvano M, Fani R. Subfunctionalization influences the expansion of bacterial multidrug antibiotic resistance. BMC Genomics 2017; 18:834. (IF= 4.257, c=3)
18. **Scoffone VC**, Chiarelli LR, Trespidi G, Mentasti M, Riccardi G, Buroni S. *Burkholderia cenocepacia* Infections in Cystic Fibrosis Patients: Drug Resistance and Therapeutic Approaches. Front Microbiol. 2017; 8:1592. (IF= 4.557, c=75)
19. Israyilova A, Buroni S, Forneris F, **Scoffone VC**, Shixaliyev NQ, Riccardi G, Chiarelli LR. Biochemical characterization of Glutamate Racemase, a new candidate drug target against *Burkholderia cenocepacia* infections. PLoS One. 2016, 11:e0167350. (IF= 3.394, c=14)
20. **Scoffone VC**, Chiarelli LR, Makarov V, Brackman G, Israyilova A, Azzalin A, Forneris F, Riabova O, Savina S, Coenye T, Riccardi G, Buroni S. Discovery of new diketopiperazines inhibiting *Burkholderia cenocepacia* quorum sensing *in vitro* and *in vivo*. Sci Rep. 2016; 6:32487. (IF= 4.847, c= 27)
21. Spadaro F*, **Scoffone VC***, Chiarelli LR, Fumagalli M, Buroni S, Riccardi G, Forneris F. The crystal structure of *Burkholderia cenocepacia* DfsA provides insights into substrate recognition and quorum sensing fatty acid biosynthesis. Biochemistry. 2016; 55:3241-50. *equal contributors. (IF= 2.777, c=6)
22. **Scoffone VC**, Ryabova O, Makarov V, Iadarola P, Fumagalli M, Fondi M, Fani R, De Rossi E, Riccardi G, Buroni S. Efflux-mediated resistance to a benzothiadiazol derivative effective against *Burkholderia cenocepacia*. Front Microbiol. 2015; 6:815. (IF= 4.360, c=11)
23. Buroni S, Matthijs N, Spadaro F, Van Acker H, **Scoffone VC**, Pasca MR, Riccardi G, Coenye T. Differential roles of RND efflux pumps in antimicrobial drug resistance of sessile and planktonic *Burkholderia cenocepacia* cells. Antimicrob Agents Chemother. 2014; 58:7424-7429. (IF= 4.540, c=31)
24. **Scoffone VC**, Spadaro F, Udine C, Makarov V, Fondi M, Fani R, De Rossi E, Riccardi G, Buroni S. Mechanism of resistance to an antitubercular 2-thiopyridine derivative that is also active against *Burkholderia cenocepacia*. Antimicrob Agents Chemother. 2014; 58:2415-2417. (IF= 4.540, c=11)
25. **Scoffone V**, Dondi D, Biino G, Borghese G, Pasini D, Galizzi A, Calvio C. Knockout of *pgdS* and *ggt* genes improves γ-PGA yield in *B. subtilis*. Biotechnol Bioeng. 2013; 110:2006-2012. (IF=4.274, c=52).

Capitoli di libri:

1. Buroni S, Bertani I, **Scoffone VC**, Venturi V. Quorum sensing and quorum quenching. In Patologia vegetale molecolare. Ed. PICCIN 2019.
2. **Scoffone VC**, Coenye T, Riccardi G, Buroni S. Antimicrobial Drug Efflux Pumps in *Burkholderia. In* Efflux-Mediated Antimicrobial Resistance in Bacteria*,* 417-438. Ed. Adis, Cham 2016.